Heat Biologics (HTBX) Announces Presentation of Topline HS-410 Phase 2 Bladder Cancer Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Roth Capital Cuts PT on Heat Biologics (HTBX) by ~27% Following HS-410 Phase 2 Data
December 1, 2016 8:25 AM ESTRoth Capital cuts its price target on Buy-rated Heat Biologics (Nasdaq: HTBX) from $2.75 to $2 following adverse HS-410 combo phase 2 data in bladder cancer, as announced on Wednesday night.
Analyst Joseph Pantginis commented today, Based on the outcome of the Phase II... More
Heat Biologics (HTBX) Shares Hit on Adverse HS-410 Combo Phase 2 Data in Invasive Bladder Cancer
December 1, 2016 8:20 AM ESTHeat Biologics (Nasdaq: HTBX) shares are getting hit early Thursday after the company announced... More
